{"preliminary_commentary":{"by_channel":{"youtube":8,"x_thread":8,"podcast":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04241185\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"KEYNOTE-992","nct_id":"NCT04241185","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-992-nct04241185. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.","label":"Pembrolizumab + Chemotherapy + Radiotherapy","type":"EXPERIMENTAL"},{"description":"Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.","label":"Placebo + Chemotherapy + Radiotherapy","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-11-01","type":"ESTIMATED"},"conditions":["Urinary Bladder Neoplasms"],"enrollment":{"count":520,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"DRUG"},{"name":"Conventional Radiotherapy (Bladder only)","otherNames":[],"type":"RADIATION"},{"name":"Conventional Radiotherapy (Bladder and pelvic nodes)","otherNames":[],"type":"RADIATION"},{"name":"Hypofractionated Radiotherapy (Bladder only)","otherNames":[],"type":"RADIATION"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Fluorouracil (5-FU)","otherNames":[],"type":"DRUG"},{"name":"Mitomycin C (MMC)","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Placebo to Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-01","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Bladder Intact Event-Free Survival (BI-EFS)","timeFrame":"Up to approximately 76 months"}],"references":[],"start_date":{"date":"2020-05-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","url":"https://clinicaltrials.gov/study/NCT04241185"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-992-nct04241185"}